MYO15B

Across TCGA pan-cancer cohorts, MYO15B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYO15B data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MYO15B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO15B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and SARC are the cancer types where MYO15B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.132	0.541	.001	6	view →
UCEC	DFS	Median	All	0.890	0.626	.036	6	view →
SARC	DFS	Median	All	0.179	0.594	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MYO15B–OV (DFS)

Open the OV breakdown →